Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | CCNK | O75909 | 3/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 6/20 | 0.49 |
| ▸ | GPR183 | P32249 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4218987 | 1.00 | NOS3 (0.53) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4221276 | 0.94 | CCNK (0.60) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4215277 | 0.94 | CCNK (0.60) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4221278 | 0.94 | CCNK (0.60) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4221675 | 0.94 | CCNK (0.60) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4222269 | 0.90 | NOS3 (0.53) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4222260 | 0.90 | NOS3 (0.53) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4223767 | 0.90 | PRKAA2 (0.52) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4219134 | 0.90 | CCNK (0.52) | NOS3NOS1NOS2CCNKCDK12 | |
| SCHEMBL4223760 | 0.90 | PRKAA2 (0.52) | NOS3NOS1NOS2CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | NOS3 4122/4885NOS1 3471/4885NOS2 3761/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | NOS3 4184/4885NOS1 3647/4885NOS2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.